964P Lenvatinib (L) and sorafenib (S) in patients (pts) with advanced or unresectable hepatocellular carcinoma (uHCC): An international, multicenter, phase IV study (STELLAR) von Peck Radosavljevic, M., Abdelgafur, A.M., Granito, A., Gasbarrini, A., Ma, Y., Mena, E., Lledó-Navarro, J.L., Presa, J., Weinmann, A., Levy, M.T., Pellicelli, A., Waldschmidt, D.T., Sørensen, H.T., Goyal, L., Ren, M., Saal, H., Okpara, C.E., Meyer, T.

Volltext